A new class of drug compounds called ENDOtollins has demonstrated the ability to reduce harmful inflammation associated with autoimmune diseases while maintaining the body's natural ability to fight infections. The compounds are being investigated as potential treatments for lupus, rheumatoid arthritis, and juvenile arthritis.
The research represents a novel approach to autoimmune disease treatment by targeting inflammation selectively rather than broadly suppressing the immune system. Traditional immunosuppressive therapies often leave patients vulnerable to infections, creating a significant clinical challenge in autoimmune disease management.